CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes

Leukemia. 2017 Oct;31(10):2254-2257. doi: 10.1038/leu.2017.223. Epub 2017 Jul 12.

Authors

M D Mathias^{1

2

3}, J T Sockolosky⁴, A Y Chang^{2

3}, K S Tan⁵, C Liu⁶, K C Garcia⁴, D A Scheinberg^{2

3}

Affiliations

¹ Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Weill Cornell Medicine, New York, NY, USA.
⁴ Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA, USA.
⁵ Department of Statistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Eureka Therapeutics, Emeryville, CA, USA.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
CD47 Antigen / antagonists & inhibitors*
Cell Line, Tumor
Cell Proliferation / drug effects
Epitopes / therapeutic use*
Humans
Macrophages / drug effects
Mice
Neoplasms / drug therapy*
Neoplasms / metabolism
Phagocytosis / drug effects
Receptors, Antigen, T-Cell / metabolism*

Substances

Antibodies, Monoclonal
CD47 Antigen
CD47 protein, human
Epitopes
Receptors, Antigen, T-Cell

Grants and funding